Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen:
doi:10.22028/D291-44362
Titel: | Eribulin-Induced Peripheral Neuropathy in Locally Advanced or Metastatic Breast Cancer: Final Analysis of the Prospective Cohort IRENE Study |
VerfasserIn: | Schmidt, Marcus Hesse, Tobias Hoffmann, Oliver Heinrich, Bernhard J. Park-Simon, Tjoung-Won Grischke, Eva-Maria Weide, Rudolf Müller Huesmann, Harald Lüdtke-Heckenkamp, Kerstin Fischer, Dorothea Zemlin, Cosima Kögel, Matthias Jia, Yan Schmitz, Helga Engelbrecht, Christian Jackisch, Christian |
Sprache: | Englisch |
Titel: | Cancers |
Bandnummer: | 17 |
Heft: | 3 |
Verlag/Plattform: | MDPI |
Erscheinungsjahr: | 2025 |
Freie Schlagwörter: | breast neoplasms peripheral nervous system diseases eribulin cohort studies prospective studies medical oncology |
DDC-Sachgruppe: | 610 Medizin, Gesundheit |
Dokumenttyp: | Journalartikel / Zeitschriftenartikel |
Abstract: | Eribulin is a preferred treatment for patients with advanced breast cancer (BC) following anthracyclines and taxanes. The final analysis of the IRENE study assessed the incidence and resolution of eribulin-induced peripheral neuropathy (EIPN), along with safety and quality of life (QoL), in patients with advanced/metastatic BC. IRENE was an observational, single-arm, prospective, multicenter cohort study. Patients aged ≥18 years with locally advanced/metastatic BC that progressed after 1–3 prior chemotherapeutic regimens received eribulin and were monitored for new-onset or worsening EIPN. Secondary endpoints included time to disease progression, safety, and health-related QoL. In total, 108 (32.2%) out of 335 patients experienced EIPN; 18 (5.4%) experienced grade ≥3 EIPN. Median time to EIPN resolution (EIPN ended or returned to baseline) was 78.7 weeks (95% CI 77.1—not estimable). Median time to disease progression was 4.5 months (95% CI 3.9–5.5). Treatment-emergent adverse events (TEAEs) occurred in 322 (96.1%) patients; serious TEAEs occurred in 185 (55.2%) patients. Incidence and resolution rates of EIPN were comparable with existing evidence from previous trials. TEAEs were consistent with the established eribulin safety profile, with no new safety signals. Eribulin treatment did not appear to affect QoL, as measured by EQ-5D-3L and EQ-VAS, or patient-reported neuropathy symptoms, as measured by the PNQ. |
DOI der Erstveröffentlichung: | 10.3390/cancers17030457 |
URL der Erstveröffentlichung: | https://doi.org/10.3390/cancers17030457 |
Link zu diesem Datensatz: | urn:nbn:de:bsz:291--ds-443620 hdl:20.500.11880/39688 http://dx.doi.org/10.22028/D291-44362 |
ISSN: | 2072-6694 |
Datum des Eintrags: | 18-Feb-2025 |
Bezeichnung des in Beziehung stehenden Objekts: | Supplementary Materials |
In Beziehung stehendes Objekt: | https://www.mdpi.com/article/10.3390/cancers17030457/s1 |
Fakultät: | M - Medizinische Fakultät |
Fachrichtung: | M - Innere Medizin |
Professur: | M - Keiner Professur zugeordnet |
Sammlung: | SciDok - Der Wissenschaftsserver der Universität des Saarlandes |
Dateien zu diesem Datensatz:
Datei | Beschreibung | Größe | Format | |
---|---|---|---|---|
cancers-17-00457.pdf | 1,46 MB | Adobe PDF | Öffnen/Anzeigen |
Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons